St. Jude OK'D on Heart Failure Device
Posted on: Tuesday, 20 March 2007, 12:01 CDT
U.S. device maker St. Jude Medical said Tuesday it has been OK'd to market its Atlas heart failure device that also treats atrial fibrillation.
The company said the system is the first heart failure device to use atrial fibrillation suppression technology.
The Atlas cardiac resynchronization therapy defibrillator helps maintain the heart's atrial rhythm by pacing slightly faster than the patient's natural heart rate, St. Jude said.
The device's AF suppression algorithm has been shown in studies to reduce the percentage of days a patient experiences AF symptoms, the company said.
Heart failure and atrial fibrillation, which St. Jude called the two new epidemics of cardiovascular disease, occur together in about 40 percent of the 5 million U.S. heart failure patients.
Source: United Press International
Related Articles
- St. Jude Medical Announces FDA and CE Mark Approvals Of QuickOpt Timing Cycle Optimization For Additional Heart Failure Devices
- St. Jude Medical Announces FDA Approvals of Current ICD and Promote CRT-D Heart Failure Devices
- St. Jude Medical Announces FDA Approval of First U.S. Heart Failure Device With AF Suppression Technology
- Orqis Medical Corporation Announces Novel Heart Failure Devices to Be Highlighted at Annual Transcatheter Cardiovascular Therapeutics (TCT) Meeting
- St. Jude Medical Announces European Approval of Atlas II ICD and Atlas II Heart Failure Devices
- St. Jude Medical Announces FDA Approval of Atlas II ICD and Atlas II Heart Failure Devices
- St. Jude Medical Announces European Approval of Epic II ICD and Epic II Heart Failure Devices; First European Implant of Epic II ICD in Switzerland
- St. Jude Medical Announces FDA Approval of Epic II ICD and Epic II Heart Failure Devices
- Medtronic Begins Landmark Clinical Trial: Cardiac Device Combines Defibrillation and Heart Monitoring; Heart-Failure Device Demonstrates Medtronic's Focus on Cardiac Disease Management
User Comments (0)

RSS Feeds